FindTrial
Sign In

Cardiotoxicity associated with anti-tumor therapy

A study for cardiotoxicity associated with anti-tumor therapy in patients with advanced lung cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900020998
Enrollment
Unknown
Registered
2019-01-24
Start date
2019-01-12
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

carditoxicity associated with anti-tumor therapy

Interventions

Group 1:receive chemotherapy
Group 2:receive targeted therapy
Group 3:receive immunotherapy

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The advanced lung caner patient: 1. at TNM stage III or higher grad than stage III; 2. with high-risk stage IB and stage II or higher that plan to receive postoperative adjuvant therapy.

Exclusion criteria

Exclusion criteria: Patients with congenital heart disease, cardiomyopathy, valvular disease and other organic heart disease;Patients with thoracic deformity or poor acoustic window conditions that affect the quality of images

Design outcomes

Primary

MeasureTime frame
myocardial strain;Troponin T;Brain natriuretic peptide;Q-T interphase;—

Countries

China

Contacts

Public ContactBai Wenjuan

Department of cardiology, West China Hospital, Sichuan University

27484197@qq.com+86 18980860406

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026